The LOVIT randomised trial evaluated intravenous vitamin C in adults with sepsis receiving vasopressors. Vitamin C had attracted attention because of its antioxidant and biological plausibility, but the trial tested whether that rationale translated into improved patient outcomes. The study did not show that intravenous vitamin C reduced death or persistent organ dysfunction. The result is clinically important because it provides high-quality evidence against routine use of high-dose intravenous vitamin C as a standard treatment for adults with sepsis. A later biological analysis of LOVIT explored whether different biological subtypes of sepsis might respond differently. That work is relevant to CritiCARE's precision-medicine theme, but it remains hypothesis-generating rather than a basis for routine treatment selection. For HCPs, the broader lesson is about evidence discipline. Mechanistically appealing therapies should not become routine before outcome-driven randomised evidence demonstrates benefit. At the same time, the biological heterogeneity of sepsis suggests that future targeted therapies may need better patient selection. The LOVIT programme therefore contributes to two linked conference messages: avoid ineffective routine adjuncts, and continue developing phenotype-informed approaches that can identify which patients might truly benefit from a specific therapy.